Tag: MYLAN
-
US FDA approves first biosimilar for certain breast and stomach cancers treatment
U.S. FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second ...
Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...
Streamlining Salaries through Payment Credit System and Other Benefits for Pharmacy Professionals: Suggestive Measures for PCI ...
Role of Artificial Intelligence in 3D Printing Personalized Medication
Blood Test Might Predict Pregnancy Due Date and Preterm Birth